Commonwealth Equity Services LLC increased its holdings in PerkinElmer, Inc. (NYSE:PKI) by 8.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,838 shares of the medical research company’s stock after purchasing an additional 730 shares during the quarter. Commonwealth Equity Services LLC’s holdings in PerkinElmer were worth $744,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also modified their holdings of the company. Dupont Capital Management Corp grew its holdings in PerkinElmer by 188.9% in the 1st quarter. Dupont Capital Management Corp now owns 1,635 shares of the medical research company’s stock worth $124,000 after acquiring an additional 1,069 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in PerkinElmer in the 1st quarter worth $127,000. Motco bought a new stake in PerkinElmer in the 1st quarter worth $199,000. Cambridge Investment Research Advisors Inc. bought a new stake in PerkinElmer in the 1st quarter worth $203,000. Finally, ING Groep NV bought a new stake in PerkinElmer in the 1st quarter worth $204,000. Institutional investors own 93.58% of the company’s stock.
In related news, Director Nicholas A. Lopardo sold 4,000 shares of the business’s stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $74.92, for a total transaction of $299,680.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Daniel R. Tereau sold 1,156 shares of the business’s stock in a transaction dated Wednesday, April 18th. The stock was sold at an average price of $77.00, for a total transaction of $89,012.00. Following the sale, the insider now directly owns 6,784 shares in the company, valued at approximately $522,368. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.
Shares of PKI opened at $73.23 on Friday. The stock has a market cap of $7.98 billion, a PE ratio of 25.25, a P/E/G ratio of 1.65 and a beta of 0.83. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.93 and a current ratio of 1.33. PerkinElmer, Inc. has a 1-year low of $62.43 and a 1-year high of $84.49.
PerkinElmer (NYSE:PKI) last announced its earnings results on Monday, April 30th. The medical research company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.02. The firm had revenue of $644.00 million for the quarter, compared to analyst estimates of $618.97 million. PerkinElmer had a net margin of 11.73% and a return on equity of 13.26%. The company’s revenue for the quarter was up 0 compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.55 EPS. research analysts expect that PerkinElmer, Inc. will post 3.61 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, August 10th. Stockholders of record on Friday, July 20th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date of this dividend is Thursday, July 19th. PerkinElmer’s payout ratio is 9.66%.
A number of equities research analysts have issued reports on the stock. ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. Robert W. Baird cut their price target on shares of PerkinElmer from $88.00 to $82.00 and set an “outperform” rating on the stock in a report on Tuesday, May 1st. Zacks Investment Research lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Wednesday, May 16th. Morgan Stanley raised their price target on shares of PerkinElmer from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, May 1st. Finally, Bank of America cut their price target on shares of PerkinElmer from $86.00 to $83.00 and set a “hold” rating on the stock in a report on Tuesday, May 1st. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $78.38.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.